Harvard Bioscience Inc. (HBIO)
0.59
-0.05 (-7.25%)
At close: Mar 24, 2025, 3:59 PM
0.62
4.79%
After-hours: Mar 24, 2025, 07:55 PM EDT
-7.25% (1D)
| Bid | 0.59 |
| Market Cap | 26.12M |
| Revenue (ttm) | 94.04M |
| Net Income (ttm) | -12.39M |
| EPS (ttm) | -0.28 |
| PE Ratio (ttm) | -2.12 |
| Forward PE | 13.68 |
| Analyst | Hold |
| Ask | 0.65 |
| Volume | 173,233 |
| Avg. Volume (20D) | 310,108 |
| Open | 0.65 |
| Previous Close | 0.64 |
| Day's Range | 0.59 - 0.66 |
| 52-Week Range | 0.59 - 4.70 |
| Beta | 1.47 |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgic...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Mar 19, 2001
Employees 330
Stock Exchange NASDAQ
Ticker Symbol HBIO
Analyst Forecast
According to 1 analyst ratings, the average rating for HBIO stock is "Hold." The 12-month stock price forecast is $4.5, which is an increase of 659.37% from the latest price.
Stock ForecastsNext Earnings Release
Harvard Bioscience Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-10.1%
Harvard Bioscience shares are trading lower. The c...
Unlock content with
Pro Subscription
